Abstract 89P
Background
Nasopharyngeal carcinoma (NPC) is an epithelial malignancy of the nasopharynx that raises public health concern in its endemic region due to its late diagnosis. The preclinical study of NPC and the bench-to-bed transition is challenged by the lack of appropriate NPC models. Conventional two-dimensional (2D) cell culture models fail to accurately replicate the complex three-dimensional (3D) structure and microenvironment of solid tumour while available 3D spheroid models for NPC do not take into account the interaction between different cell types.
Methods
In this study, we aimed to generate 3D multicellular tumour spheroids (MCTSs) to mimic the in vivo tumour architecture and microenvironment. Homotypic MCTSs were generated using Epstein-Barr virus (EBV)-positive (C666-1, NPC43) and EBV-negative NPC (HK-1) cell lines, respectively, while heterotypic MCTSs involve co-culturing EBV-positive and EBV-negative cells with stromal cells including fibroblasts (MRC-5) and HUVEC). Spheroids were constructed using the scaffold-based technique, and morphological examination was performed using light microscopy and fluorescence microscopy to characterize the spheroid size, shape and cellular organization.
Results
Homotypic and heterotypic MCTSs generated from EBV-positive and EBV-negative cell lines form spherical aggregates. H&E staining of the MCTSs demonstrated in vivo tumour characteristics, including 3D organisation, scanted cytoplasm, irregular and enlarged nuclei, and necrotic regions. EBV+ cell lines generally formed homotypic MCTSs with more compact and spherical morphology, while homotypic MCTSs generated from EBV- cell lines are less compact and displayed alveolar-like shape. The presence of NPC cells, fibroblasts, and endothelial cells in the heterotypic MCTSs were confirmed using immunofluorescence staining.
Conclusions
Homotypic and heterotypic MCTSs were generated from both EBV- and EBV+ NPC cells. The MCTSs generated replicates the in vivo tumour features in vitro. This model would serve as a platform for the study of intercellular interactions and evaluation of potential therapeutic responses.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Malaysia Ministry of Higher Education.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
142P - Lipidomic signature in response to omega-3 fatty acids and γ-linolenic acid supplementation in breast cancer patients receiving aromatase inhibitors
Presenter: Vesna Vucic
Session: Cocktail & Poster Display session
Resources:
Abstract
143P - A tailored histology-driven molecular profiling algorithm proposal for salivary gland cancers
Presenter: Simone Rota
Session: Cocktail & Poster Display session
Resources:
Abstract
144P - Is it time to incorporate next generation sequencing of body fluids for detection of circulating tumor DNA (ctDNA) alterations?
Presenter: Aditya Shreenivas
Session: Cocktail & Poster Display session
Resources:
Abstract
145P - Unveiling the molecular landscape of head and neck cancer: Pathway dysregulations and potential therapeutic targets
Presenter: Rajeev Vijayakumar
Session: Cocktail & Poster Display session
Resources:
Abstract
146P - ESR1 fusions as potential mechanism of resistance to endocrine therapy in metastatic breast cancer
Presenter: Sewanti Limaye
Session: Cocktail & Poster Display session
Resources:
Abstract
147P - Clinical characteristics and outcomes in non-small cell lung cancer patients harboring rare mutations: A single center real-world data
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Diversity of genomic mechanisms of resistance to endocrine therapy in ER+ breast cancer
Presenter: Prithika Sritharan
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Assessing treatment options for gynaecological cancers (GC) using next-generation sequencing (NGS): A real-world analysis
Presenter: Álvaro García
Session: Cocktail & Poster Display session
Resources:
Abstract
150P - Prevalence of DPYD variants in 1478 cancer patients receiving fluoropyrimidine chemotherapy: A real-world data analysis
Presenter: Bahaaeldin Baraka
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Unravelling the limitations of next-generation sequencing (NGS)-based liquid biopsy (LB) across solid tumors: The PREICO-LB project
Presenter: Cinta Hierro
Session: Cocktail & Poster Display session
Resources:
Abstract